Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
64 studies found for:    Behcet's Disease
Show Display Options
Rank Status Study
1 Recruiting A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Condition: Behcet Disease
Intervention: Drug: Infliximab
2 Terminated Stem Cell Transplantation in Ocular Lesions of Behcet's Disease
Conditions: Retinitis;   Behcet's Syndrome
Intervention: Biological: Autologous Stem Cell Transplantation
3 Active, not recruiting Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
Condition: Behcet's Disease
Intervention:
4 Completed Psychological Symptoms in Patients With Behcet's Disease by SCL90-R
Condition: Behcet's Syndrome
Intervention:
5 Completed Behçet's Disease and Eosinophil Cationic Protein
Condition: Behçet's Disease
Intervention: Other: eosinophil cationic protein
6 Completed
Has Results
A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease
Condition: Intestinal Behçet's Disease
Intervention: Biological: Adalimumab
7 Terminated Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
Condition: Behcet's Disease Uveitis
Interventions: Drug: Placebo;   Drug: Gevokizumab
8 Recruiting A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients
Condition: Intestinal Behcet's Disease (BD)
Intervention:
9 Completed MEVALONATE KINASE GENE MUTATIONS AND THEIR CLINICAL CORRELATIONS IN BEHÇET'S DISEASE
Condition: Behçet's Disease
Intervention:
10 Completed Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease
Condition: Behcet's Syndrome
Interventions: Drug: Colchicine;   Drug: Placebo
11 Not yet recruiting Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
Condition: Behçet Disease
Intervention: Drug: Subcutaneous Ustekinumab
12 Completed Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Conditions: Behcet's Disease;   Behcet Syndrome;   Neuro-Behcet's Disease
Intervention: Drug: TA-650
13 Unknown  Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
Conditions: Behcet Syndrome;   Uveal Disease
Intervention: Drug: Etanercept, Methotrexate, Prednisolone
14 Unknown  Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease
Conditions: Ocular Behcet's Disease,;   Non-Infectious Uveitis;   Refractory Uveitis
Intervention: Drug: flucinolone acetonide
15 Completed Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study
Conditions: Behçet's Disease;   Uveitis
Intervention: Drug: Intravitreal Infliximab
16 Recruiting 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement
Condition: Behcet Disease
Intervention: Drug: drug administration
17 Unknown  The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease
Condition: Behcet's Disease
Interventions: Drug: methylorednisolone;   Other: dextrose water 5%
18 Recruiting A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease
Condition: Behcet Syndrome
Interventions: Drug: Apremilast (CC-10004);   Drug: Placebo
19 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
Condition: Behcet Syndrome
Interventions: Drug: Apremilast (CC-10004);   Drug: Placebo
20 Completed Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease
Condition: Behcet's Syndrome
Interventions: Drug: Rituximab;   Drug: Cytotoxic Combination

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.